AEON Biopharma shares are trading lower after the company announced that the preliminary top-line results from its interim analysis of its Phase 2 trial with ABP-450 did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
AEON Biopharma's stock price dropped following the announcement that ABP-450, its Phase 2 trial drug, failed to meet the primary endpoint in preliminary top-line results.
May 03, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AEON Biopharma's shares are expected to face downward pressure in the short term due to the negative outcome of the ABP-450 Phase 2 trial.
The failure of ABP-450 to meet its primary endpoint in a Phase 2 trial is a significant setback for AEON Biopharma, likely leading to decreased investor confidence and a short-term decline in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100